Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Video Panel: How China Inc. Sells Latest Therapies In An Untapped Market

Top Execs Discuss If Country Can Become True Global Player

Executive Summary

During the “Road to Commercialization” panel session during EBD/Informa Connect's recent annual ChinaBio partnering event, senior executives from top Chinese biotechs along with a leading contract manufacturing organization and venture fund shared views on biologics commercialization in China. Partnerships to accelerate the process, as well as the future commercial direction of novel biologics in their fastest-growing market worldwide, were also discussed.

You may also be interested in...



How China Inc. Aims To Take Over Cell Therapy Dominance

Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.

Roche, Sanofi Double Down On Post-Coronavirus China With Oncology Alliances

In a bid widely seen as a move to double down on their “in China for China” strategy, Sanofi and Roche have formed new drug development alliances with local innovative players potentially worth billions.

Lost In Translation? New Zoonotic Virus Naming Gets China's Largest Physician Platform In Trouble

China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel